Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

INTRODUCTION: In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing–remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive extensions (NCT00930553; NCT02255656). This post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Samuel F., Aburashed, Rany A., Alroughani, Raed, Chan, Andrew, Dive, Dominique, Eichau, Sara, Kantor, Daniel, Kim, Ho Jin, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, Scott, Thomas, Sharrack, Basil, Wiendl, Heinz, Chung, Luke, Daizadeh, Nadia, Baker, Darren P., Vermersch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571457/
https://www.ncbi.nlm.nih.gov/pubmed/34165694
http://dx.doi.org/10.1007/s40120-021-00262-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571457/
https://www.ncbi.nlm.nih.gov/pubmed/34165694
http://dx.doi.org/10.1007/s40120-021-00262-3

Ejemplares similares